KenSujinHoMD

Infectious Disease • Pittsburgh, PA

Instructor, Medicine, University of Pittsburgh School of Medicine

Join to view full profile

Dr. Ho is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ho's full profile

Already have an account?

Office
200 Lothrop St
Falk Medical Building Suite 3a
Pittsburgh, PA 15213
Phone+1 412-648-6924

Education & Training

UPMC Medical EducationFellowship, Infectious Disease, 2008 - 2010
UPMC Medical EducationResidency, Internal Medicine, 2004 - 2007
University of Maryland School of MedicineClass of 2004

Certifications & Licensure

PA State Medical License 2004 - 2024
NJ State Medical License 2021 - 2023
MD State Medical License 2006 - 2018
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2012-2015
Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2012-2015

Clinical Trials

Dipyridamole for Immune Activation in HIV Start of enrollment: 2014 Jul 01
Completed
Phase 1, Phase 2
Optimization of a Tenofovir Enema for HIV Prevention Start of enrollment: 2016 Oct 01
Completed
Phase 1
Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults Start of enrollment: 2018 May 10
Completed
Phase 1
Griffithsin-based Rectal Microbicide for PREvention of Viral ENTry (PREVENT) Start of enrollment: 2019 Jul 10
Terminated
Phase 1
Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs Start of enrollment: 2020 Aug 31
Completed
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention.
Sharon A Riddler, Clifton W Kelly, Craig J Hoesley, Ken S Ho, Jeanna M Piper
The Journal of Infectious Diseases. 2024-09-23
Acceptability of a rectal microbicide douche for HIV prevention: a mixed-methods analysis of a first-in-human formulation pilot study.
Rebecca Giguere, Iván C Balán, Cody Lentz, Curtis Dolezal, Alex Carballo-Diéguez
Sexually Transmitted Infections. 2024-09-05
1 citations
History of Rectal Product Use and Country of Residence Influence Preference for Rectal Microbicide Dosage Forms Among Young Sexual and Gender Minorities: A Multi-count...
Rebecca Giguere, Iván C Balán, Bryan A Kutner, Seul Ki Choi, Ryan Tingler
AIDS and Behavior. 2024-08-01

Journal Articles

Association of Urinary Biomarkers of Kidney Injury with Estimated GFR Decline in HIV-Infected Individuals Following Tenofovir Disoproxil Fumarate Initiation
Rebecca Scherzer, Frank J Palella, Vasantha Jotwani, Mardge H Cohen, Carl Grunfeld, Mallory D Witt, Ken Ho, Chirag R Parikh, Mary Young, Anjali Sharma, Michael G Shlipak, Journal of the American Society of Nephrology

Press Mentions

The COVID-19 Vaccination Experience of Non-English Speaking Immigrant and Refugee Communities of Color: A Community Co-Created StudyOctober 25th, 2022
Researchers Report Trial Results of Rectal Microbicides at HIV R4P Virtual ConferenceFebruary 3rd, 2021
14 Aug Short Term PReP Can Help Protect Men from HIV During VacationAugust 14th, 2020
Join now to see all